<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365049</url>
  </required_header>
  <id_info>
    <org_study_id>HepBilPan001</org_study_id>
    <nct_id>NCT04365049</nct_id>
  </id_info>
  <brief_title>Radiotherapy Plus Anti-programmed Death Gene-1 (PD-1) and Apatinib for Unresectable Hepato-bilio-pancreatic Cancers</brief_title>
  <official_title>Combination of Radiotherapy, Anti-PD-1 Antibody and Apatinib for Patients With Unresectable Hepato-bilio-pancreatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective and observational cohort study. The purpose is to investigate the
      efficacy and safety of radiotherapy combined with anti-PD-1 antibody and apatinib compared
      with gemcitabine and cisplatin in patients with unresectable hepato-bilio-pancreatic cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will prospectively collect 150 patients who receive radiotherapy+anti-PD-1+apatinib or
      gemcitabine and cisplatin. Data will be stored in a private database. The process of data
      collection will be supervised and regular data examination will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>two years</time_frame>
    <description>defined as the time from randomization until disease progression or death from any cause, whichever happens first. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free. Patients not having an event will be censored at the date last seen alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>two years</time_frame>
    <description>defined as the time from randomization until death from any cause. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive. Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>two years</time_frame>
    <description>adverse events during the treatment period using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>two years</time_frame>
    <description>measured according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 by means of computed tomography (CT) or magnetic resonance imaging (MRI) at each follow-up.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepato-Biliary Neoplasm</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Radiotherapy</condition>
  <condition>PD-1</condition>
  <condition>Apatinib</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Patients in treatment group will receive anti-PD-1 antibody intravenously every three weeks and apatinib 250mg per day until disease progression, unacceptable toxicity, death or withdrawal. Concurrent external beam radiation will be initiated after one course of anti-PD-1 treatment. The total radiation dose is over 40Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine+cisplatin</arm_group_label>
    <description>Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Concurrent external beam radiation will be initiated after one course of anti-PD-1 treatment. The total radiation dose is over 40Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Gemcitabine+cisplatin</intervention_name>
    <description>Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.</description>
    <arm_group_label>Gemcitabine+cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti PD-1</intervention_name>
    <description>Patients will receive anti-PD-1 antibody intravenously every three weeks until disease progression, unacceptable toxicity, death or withdrawal.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Patients will receive apatinib 250mg per day until disease progression, unacceptable toxicity, death or withdrawal.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Unresectable hepato-bilio-pancreatic cancer patients proved by pathology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-75 years;

          2. Unresectable hepato-bilio-pancreatic cancer patients proved by pathology;

          3. No previous radiotherapy or immunotherapy;

          4. Eligible for radiotherapy and immunotherapy after evaluation of specialized experts;

          5. At least one measurable lesion based on RECIST 1.1 criteria;

          6. Child-Pugh A class;

          7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;

          8. Adequate hematologic, hepatic and renal function: absolute neutrophil count (ANC) ≥
             1.5x10^9/L, Hb ≥ 90g/L, platelet (PLT) ≥ 100 x10^9/L, albumin ≥ 28g/L, total bilirubin
             &lt; 1.5×ULN at diagnosis or after biliary drainage, alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) &lt; 5×ULN, blood urea nitrogen (BUN)&lt;1.5×ULN,
             creatine&lt;1.5×ULN, creatinine clearance rate ≥ 45ml/min;

          9. At least 12 weeks of life expectancy.

        Exclusion Criteria:

          1. Have acute or chronic active hepatitis B or C virus (HBV or HCV), HBV-DNA＞2000IU/ml or
             10^4 copy/ml; HCV-RNA＞10^3 copy/ml; both HBsAg and HCV antibody are positive. If the
             related results become lower than above standards after anti-viral treatment, the
             patients are qualified for enrolment;

          2. Have metastasis in extrahepatic distant organs including lung, central nervous system,
             bone and etc. Or extrahepatic lymph node metastasis beyond abdomen;

          3. Have risky bleeding events requiring transfusion, operation or local therapies,
             continuous medication in the past 3 months;

          4. Have thromboembolism in the past 6 months, including myocardial infarction, unstable
             angina, stroke or transient ischemic attack, pulmonary embolism, deep vein thrombosis;

          5. Have taken aspirin (＞325mg/day) or other antiplatelet drugs continuously for 10 days
             or more within 2 weeks before enrolment;

          6. Uncontrollable hypertension, systolic pressure＞140mmHg or diastolic pressure＞90mmHg
             after best medical care, or history of hypertensive crisis or hypertensive
             encephalopathy;

          7. Symptomatic congestive heart failure (NYHA class II-IV). Symptomatic or
             badly-controlled arrhythmia. Congenital long QT syndrome or modified QTc＞500ms upon
             screening;

          8. Have active autoimmune diseases that require systemic treatment within 2 years before
             enrolment;

          9. Active tuberculosis, having antituberculosis therapy at present or within 1 year;

         10. Have a known history of prior invasive malignancies within 5 years before enrolment;

         11. Pregnant or breastfeeding women, or expecting to conceive or father children within
             the projected duration of the trial;

         12. Have other uncontrollable comorbidities;

         13. Infection of HIV, known syphilis requiring treatment;

         14. Allergic to elements of anti-PD-1 drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Kuang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Kuang, PhD</last_name>
    <phone>008687755766</phone>
    <phone_ext>8576</phone_ext>
    <email>kuangm@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenwei Peng, PhD</last_name>
    <phone>008687755766</phone>
    <phone_ext>8576</phone_ext>
    <email>pzhenw@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming Kuang</investigator_full_name>
    <investigator_title>The vice president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

